The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (A) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof.

A polymer-metal oxide complex, comprising a metal oxide particle located at the core and a polymer modified on the surface of the metal oxide particle, the polymer being provided with functional groups capable of bonding with a metal in the metal oxide, the density of the binding sites of the polymer and the surface of the metal oxide particle being greater than two sites/square nanometer. Also disclosed are a preparation method for the polymer-metal oxide complex, and applications of the polymer-metal oxide complex as a nuclear magnetic resonance contrast agent and as an iron supplement. The polymer-metal oxide complex has a significantly extended in vivo circulation time and effectively overcomes the defect that existing contrast agents cause hypersensitivity, which in addition to the superparamagnetic and iron metabolism participation functions of the complex, enables the complex to be applied as a magnetic resonance imaging contrast agent and as an iron supplement treating iron-deficiency anaemia.

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

The present invention is directed to compositions useful in assembling vesicles. The composition comprises a first block copolymer; a plurality of first inorganic nanoparticles; a second block copolymer; and a plurality of second inorganic nanoparticles or a plurality of small molecules. The composition is characterized by the ability to self-assemble into a vesicle. Also provided is a method of making a composition for delivery of a therapeutic agent and a method of using the vesicles as imaging agents.

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

A contrast agent for MRI imaging diagnostics. The contrast agent is comprised of a nano-fuel cell coupled to at least one ligand for specific binding to a cell membrane. An imaging method for the visualisation of tumor cells using the contrast agent and a method for non invasive treatment of tumor cells using the contrast agent.

A pharmaceutical composition includes a plurality of metal nanoparticles and at least one therapeutic agent. Each of the metal nanoparticles includes a core and a stabilizing agent coated on a surface of the core. The at least one therapeutic agent is attached to the stabilizing agent of the metal nanoparticles. Each of the therapeutic agent is an amphiphilic compound and has at least one hydrophobic chain interacting with the stabilizing agent. The pharmaceutical composition may further include a polymer shell encapsulating the metal nanoparticles and the therapeutic agent for enabling controlled release of the therapeutic agent. The pharmaceutical compositions are bifunctional and may be used for diagnosing and treating cancer. Methods for using the pharmaceutical compositions in conjunction with radiation therapy to diagnose and treat cancer are also provided.

The present application provides a polymer microsphere and a preparing method thereof. The polymer microsphere includes a core and a shell coating the core; the core includes at least two magnetic particles and a dispersion located between two neighboring magnetic particles; the shell includes a main shell body and a modifying layer, and the modifying layer is located on one side of the main shell body that is away from the magnetic particles; and a material of the dispersion, a material of the main shell body and a material of the modifying layer are the same. The magnetic particles in the polymer microsphere have a good dispersibility, and, when heated, the magnetic attraction force and the magnetic responsiveness of the polymer microsphere can nearly maintain unchanged.

The present invention provides a nanoparticle including at least one polyvinyl alcohol) (PVA) having a molecular weight of from about 10 kDa to about 200 kDa, substituted with one or more moieties selected from: a therapeutic agent having a boronic acid moiety, wherein the therapeutic agent is covalently linked to the PVA via a boronate ester bond; a crosslinking group having a disulfide moiety, wherein the crosslinking group is covalently linked to the PVA, and a porphyrin, wherein the porphyrin is covalently linked to the PVA. Use of the nanoparticles for tumor detection and the treatment of diseases, including methods for photodynamic therapy and photothermal therapy, are also described.

The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (A) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof.